Tokyo:4523

"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel

Retrieved on: 
金曜日, 7月 12, 2024

TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD).

Key Points: 
  • TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD).
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.
  • LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • LEQEMBI has also been approved in the U.S., Japan, China, South Korea and Hong Kong, and is being marketed in the U.S. Japan and China.

"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong

Retrieved on: 
木曜日, 7月 11, 2024

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.
  • LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • Hong Kong is the fifth approval, following approvals in the U.S., Japan, China, and South Korea.
  • LEQEMBI's approval in Hong Kong is based on the large global Phase 3 Clarity AD study.

Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)

Retrieved on: 
火曜日, 7月 2, 2024

Based on the agreement, Eisai now owns all rights to FZEC and will solely conduct the global development and commercialization of the agent.

Key Points: 
  • Based on the agreement, Eisai now owns all rights to FZEC and will solely conduct the global development and commercialization of the agent.
  • Eisai will accelerate the development of the agent as a high priority with the hope to deliver it to patients as early as possible.
  • Eisai positions oncology as a key franchise area and aims to contribute toward the cure of cancers by exploring the depths of human biology.
  • FZEC development for refractory cancers is a testament of our dedication to addressing the unmet medical needs of patients with cancer.

Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China

Retrieved on: 
金曜日, 6月 28, 2024

LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia.

Key Points: 
  • LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia.
  • China is the third country to launch LEQEMBI following the United States and Japan.
  • LEQEMBI is the world's first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • (2)
    Dosage and administration: The usual dose of lecanemab (recombinant) is 10mg/kg infused intravenously over approximately 1 hour, once every 2 weeks.